Send me real-time posts from this site at my email
Motley Fool

Kodak Gets a Boost as Regulatory Watchdog Finds No Loan Wrongdoing

Eastman Kodak's (NYSE: KODK) bid to turn itself from a photography leader into a pharmaceutical company got a boost today after a government regulatory watchdog said the U.S. International Development Finance Corp. did nothing wrong in awarding the company a $765 million government loan to assist in the transformation.

This past summer an internal investigation cleared Kodak of any wrongdoing in awarding top executives millions of dollars in stock options just before announcing it had won the loan. The results of the investigation have investors thinking it's all full-speed ahead. They should probably think again.

Image source: Getty Images.

Still no clear path forward

It was already a curious decision by Kodak to make the leap into manufacturing certain generic drugs, including the antimalarial drug hydroxychloroquine, which was seen as having some potential in combating COVID-19. But despite giving itself a clean bill of health for its actions, the all-clear signal hasn't been accepted yet by the Securities & Exchange Commission (SEC) or Congress, both of which also launched probes into the matter.

The report by the inspector general of the U.S. International Development Finance Corp. (DFC) exonerating itself from any impropriety says there was no evidence of conflicts of interest involving agency employees or any misconduct on the part of the agency's officials.

However, the report also notes the investigation was very narrow as the agency "focused our review on issues within DFC purview and authority. We did not review conduct by Kodak or non-DFC personnel."

Kodak's stock barreled higher when the loan was originally announced and then crashed after it was put on hold due to questions around the alleged improprieties that occurred with it. The market reacted to the inspector general's report as if Kodak were about to get the loan again, sending shares nearly 90% higher in morning trading, though they've since sank back to around a 60% gain at midday.

10 stocks we like better than Eastman Kodak
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Eastman Kodak wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of November 20, 2020

Rich Duprey has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.


Source

Popular posts

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue